Louisiana state seal Louisiana Ethics Administration Program
Home Charges Search EAB Decisions Search
. 4 <br /> �,,, STATE OF LOUISIANA <br /> gyp,OF LOU''. <br /> F•�t`vo �jy'c DEPARTMENT OF STATE CIVIL SERVICE <br /> ;��;, LOUISIANA BOARD OF ETHICS <br /> 11';41.1%'' <br /> iiii,;�,�, ��III P.O.BOX 4368 <br /> ih <br /> 1.% BATON ROUGE,LA 70821 <br /> oN"' `' (225)219-5600 <br /> FAX:(225)381-7271 <br /> 1-800-842-6630 <br /> www.ethics.state.la.us <br /> March 21, 2016 <br /> Dr. James Cardelli <br /> 603 Avignon Ln <br /> Shreveport, LA 71115 <br /> Re: Ethics Board Docket No. 2015-1382 <br /> Dear Dr. Cardelli: <br /> The Louisiana Board of Ethics, at its March 18, 2016 meeting, considered your request <br /> for an advisory opinion regarding the application of the post-employment restrictions set <br /> forth in the Code of Governmental Ethics. You provided the following background <br /> information for consideration in connection with your request: <br /> You were employed as a professor in the Microbiology and Immunology Department of <br /> the Louisiana State University Health Sciences Center in Shreveport (Center) from 1985 <br /> until December 31, 2015. In addition to teaching classes, you were responsible for <br /> running a research laboratory. Separate and apart from your role as a professor, you also <br /> served as the Director of the Center's Innovative North Louisiana Experimental <br /> Therapeutics (INLET) program from 2012 through 2015, for which you received no <br /> additional compensation. INLET consists of a multi-institutional program focused on <br /> discovering and marketing natural products and repurposed drugs that are used to treat <br /> one human disease and repositioning them to treat other diseases in humans. The <br /> research conducted as part of INLET includes independent research, federally-supported <br /> research, and company-sponsored research programs. Finally, as Director of INLET and <br /> the principal investigator, you wrote the first sponsored research agreement (SRA) <br /> funded by K94 Discoveries, Inc., a biotechnology company, that ended in early 2015. <br /> As President of Segue Therapeutics, LLC, a biotechnology company that you registered <br /> with the Secretary of State's Office on January 6, 2016, you are currently involved in <br /> acquiring first round seed money to develop and commercialize existing drugs for new <br /> medical purposes. Some of this money will be sent to the Center/INLET in the form of <br /> SRAs to perform research to further develop repurposed drugs for treatment of human <br /> diseases. However, you will not be conducting the research that will be funded by the <br /> SRAs. Additionally, Segue Therapeutics, LLC, intends to license technologies that you <br /> developed while employed with the Center. Legal counsel will negotiate the SRAs with <br /> the Center and the licensing contracts with the Center's Office of Sponsored Programs <br /> and Technology Transfer (OSPTT). Finally, you will serve as an uncompensated advisor <br /> AN EQUAL OPPORTUNITY EMPLOYER <br />